Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 94 of 116

  1. Engineered mitochondrial vaccine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Solid Tumor Malignancies

    phase 1 mab active

    1 trial

  2. Entinostat

    Syndax Pharmaceuticals

    Neoplasms

    phase 1 small molecule completed

    2 trials

  3. Entinostat

    Syndax Pharmaceuticals

    Fallopian Tube Cancer

    phase 1 small molecule terminated

    1 trial

  4. Entinostat

    Syndax Pharmaceuticals

    Metastatic Breast Cancer

    phase 1 small molecule completed

    1 trial

  5. Entinostat

    Syndax Pharmaceuticals

    Pancreas Cancer

    phase 1 small molecule terminated

    1 trial

  6. Enzalutamide

    CORCEPT THERAPEUTICS INC

    Prostate Cancer

    phase 1 small molecule completed

    1 trial

  7. Erwinase

    Jazz Pharmaceuticals Ireland Limited

    Acute Lymphoblastic Leukemia

    phase 1 small molecule completed

    1 trial

  8. Erwinia Chrysanthemi asparaginase

    Jazz Pharmaceuticals Ireland Limited

    Acute Lymphoblastic Leukemia (ALL)

    phase 1 small molecule terminated

    1 trial

  9. Etrumadenant

    Arcus Biosciences

    Non-small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

  10. Etrumadenant

    Arcus Biosciences

    TNBC - Triple-Negative Breast Cancer

    phase 1 small molecule completed

    1 trial

  11. Etrumadenant

    Arcus Biosciences

    Non Small Cell Lung Cancer Metastatic

    phase 1 small molecule completed

    1 trial

  12. Evixapodlin

    Gilead Sciences Ireland UC

    Advanced Solid Tumors

    phase 1 small molecule terminated

    1 trial

  13. Evorpacept

    ALX ONCOLOGY HOLDINGS INC

    Bladder Cancer

    phase 1 small molecule completed

    1 trial

  14. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Metastatic Cancer

    phase 1 small molecule completed

    1 trial

  15. Ex-vivo expanded allogeneic γδ T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML (Acute Myelogenous Leukemia)

    phase 1 mab active

    1 trial

  16. Ex-vivo expanded allogeneic γδT cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-Hodgkin's Lymphoma (NHL)

    phase 1 mab active

    1 trial

  17. FATE-NK100

    Zafatek

    HER2 Positive Gastric Cancer

    phase 1 small molecule completed

    1 trial

  18. FHD-286

    Foghorn Therapeutics

    Metastatic Uveal Melanoma

    phase 1 small molecule terminated

    1 trial

  19. FHD-609

    Foghorn Therapeutics

    Advanced Synovial Sarcoma

    phase 1 small molecule terminated

    1 trial

  20. FP-1039

    Prime Medicine

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  21. FPA144

    Prime Medicine

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  22. FPA150

    Prime Medicine

    Breast Cancer

    phase 1 mab terminated

    1 trial

  23. FPI-2505-001

    Lacuna Pharma Pty Ltd

    small cell lung cancer, non-smallcell lung cancer, colorectal cancer, breast cancer, Pancreatic cancer and gastric cancer

    phase 1 other active

    1 trial

  24. FPT155

    Prime Medicine

    Advanced Solid Tumors

    phase 1 mab terminated

    1 trial

  25. FT500

    Zafatek

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  26. FT516

    Zafatek

    Acute Myelogenous Leukemia

    phase 1 small molecule terminated

    1 trial

  27. FT516

    Zafatek

    Solid Tumor, Adult

    phase 1 small molecule terminated

    1 trial

  28. FT522

    Zafatek

    Relapsed/Refractory B-Cell Lymphoma

    phase 1 small molecule completed

    1 trial

  29. FT536

    Zafatek

    Non Small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  30. FT538

    Zafatek

    Solid Tumor, Adult

    phase 1 small molecule terminated

    1 trial

  31. FT538

    Zafatek

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial

  32. FT596

    Zafatek

    Diffuse Large B Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  33. FT596

    Zafatek

    Lymphoma, B-Cell

    phase 1 small molecule terminated

    1 trial

  34. FT819

    Zafatek

    Lymphoma, B-Cell

    phase 1 small molecule active

    1 trial

  35. FT825

    Zafatek

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  36. FT836

    Zafatek

    Non-Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  37. FURMO-002

    ArriVent BioPharma

    Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR or HER2 kinase domain mutations

    phase 1 other active

    1 trial

  38. FYB206-C1-01

    Formycon AG

    Melanoma: Adjuvant treatment of patients with Stage IIB, IIC, or III melanoma following complete resection

    phase 1 other active

    1 trial

  39. Fast Dual CAR-T Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Lymphoma

    phase 1 mab terminated

    1 trial

  40. First in human study of the infusion of ARI00...

    The George Institute

    Relapsed/refractory B-cell aggressive lymphoma

    phase 1 other active

    1 trial

  41. First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors

    Daiichi Sankyo

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  42. First-in-Human trial of DS9051b in participants with advanced solid tumors

    Daiichi Sankyo

    Advanced or Metastatic Adrenocortical Carcinoma (ACC), Metastatic Castration-resistant Prostate Cancer (CRPC)

    phase 1 other active

    1 trial

  43. First-in-human (FIH) Study of DS-1471a in Subjects with Advanced Solid Tumors

    Daiichi Sankyo

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  44. First-in-human Trial of DS-2243a in Participants with Advanced Solid Tumors

    Daiichi Sankyo

    Advanced Solid Tumor

    phase 1 other active

    1 trial

  45. Follicle Stimulating Hormone Receptor T Cells

    Anixa Biosciences Inc

    Ovarian Cancer

    phase 1 small molecule active

    1 trial

  46. Fostamatinib 100 mg bid and Paclitaxel

    RIGEL PHARMACEUTICALS INC

    Ovarian Cancer

    phase 1 small molecule completed

    1 trial

  47. Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)

    RIGEL PHARMACEUTICALS INC

    Pancreatic Ductal Adenocarcinoma (PDAC)

    phase 1 other active

    1 trial

  48. Furmonertinib

    ArriVent BioPharma

    Non-Small Cell Lung Cancer (NSCLC)

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.